Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase - Wikidata - wikimedia - TriplyDB

Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase

Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase

http://www.wikidata.org/entity/Q27690120

about

Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free-Energy Perturbation (FEP)Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations?Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle.Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.Recent advances in development of imidazo[1,2-a]pyrazines: synthesis, reactivity and their biological applications.Targeted therapy for chronic lymphocytic leukemia: current status and future directions.Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.Repairing the basic defect in cystic fibrosis - one approach is not enough.New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.Oxindole-based SYK and JAK3 dual inhibitors for rheumatoid arthritis: designing, synthesis and biological evaluation.Breakthrough therapies in B-cell non-Hodgkin lymphoma.3-aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors.Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.BI 1002494, a Novel Potent and Selective Oral Spleen Tyrosine Kinase Inhibitor, Displays Differential Potency in Human Basophils and B Cells.Syk inhibitors in clinical development for hematological malignancies.Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate Optimization.The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients.Identification of new dual spleen tyrosine kinase (Syk) and phosphoionositide-3-kinase δ (PI3Kδ) inhibitors using ligand and structure-based integrated ideal pharmacophore models.Tyrosine Kinase SYK is a Potential Therapeutic Target for Liver Fibrosis.Myeloid cell-mediated renal injury in rapidly progressive glomerulonephritis depends upon spleen tyrosine kinase.Spleen tyrosine kinase contributes to acute renal allograft rejection in the rat.Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).Discovery of benzylidene derivatives as potent Syk inhibitors: synthesis, SAR analysis, and biological evaluation.An inhibitor of spleen tyrosine kinase suppresses experimental crescentic glomerulonephritis.

P2860

Q26744277-19DC1AC4-BCE7-4F5C-8453-28DDC3CCCCEC Q26751006-BBD63499-BD83-46A6-BFBB-4A1437194D55 Q27702174-FB5C8C49-DD27-4F07-8397-9E25B208F6A5 Q27726998-00115D57-E2CC-49F2-91CE-C74D6AA03A09 Q27853177-0C118F45-6998-42FD-922F-6AEA642207C0 Q28257366-4EA3EC31-6B06-4C16-ADB8-A73024286C17 Q35434205-EE4AC66A-A5F0-4366-8351-DA4F38996041 Q35582737-D957D57B-2EBB-4505-B83C-8EE5C2FA6E3F Q35706804-8877D932-1AEA-4DD5-B984-7CF98C039F2A Q36876967-09F11A09-C9BD-4FE5-BCB6-F748D4D06850 Q36920433-9E5A1625-08EB-4A46-99D7-BA2B22C9F44B Q38309043-981055B8-1211-4EAD-AE8F-D8F3CC9A418B Q38331701-57537D82-41BB-4979-A2E1-0A71BCF31C0D Q38594364-1495844E-9181-4E29-8CAF-482C961A0DA5 Q38594795-F03D5FB8-7C50-4C39-8DF6-28C1EDF809EF Q38646974-6C81ABA6-DD8D-410C-93D4-333B47D8915A Q38655324-5AF8B7A4-CDD1-47AD-9A83-2F61B0F77E4D Q38708600-99599F01-5AD0-4B45-AC17-15ADDEFA2953 Q38766412-05142895-44F3-4888-9AF0-96581F1FD4C1 Q38798340-7887E30E-F1BF-4A97-B5AC-703340282071 Q39860557-EC134309-CCDC-4C70-BA8E-05139030A249 Q42011012-13DA01C6-BA21-4A1C-A6A9-3B40E06DCF07 Q45397146-39B22180-0515-45F2-9400-75E8952F1563 Q48120395-3FE9F148-125A-417C-B556-936512B7A0F2 Q51632843-E9FECF69-5BA3-4E48-B700-DD013294C2C5 Q52656283-2188DDD3-53B9-47D9-B507-7928B6B9A406 Q53387884-1895CAA1-99E4-4D79-A32B-05ACB96719A5 Q53656379-07016AE5-9DB1-46E1-A1B4-93C9D5250AC2 Q54172917-EC961588-15C3-4B24-A52F-82D9691AD8F6 Q54268657-76493FC1-4F96-4A52-A249-C9C2082EE085 Q55442953-55BBD1F4-184F-4E25-BC66-245ADC6B75C7

P2860

Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase

http://www.wikidata.org/entity/Q27690120

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Discovery of GS-9973, a select ...... itor of spleen tyrosine kinase

@ast

Discovery of GS-9973, a select ...... itor of spleen tyrosine kinase

@en

Discovery of GS-9973, a select ...... itor of spleen tyrosine kinase

@nl

type

label

Discovery of GS-9973, a select ...... itor of spleen tyrosine kinase

@ast

Discovery of GS-9973, a select ...... itor of spleen tyrosine kinase

@en

Discovery of GS-9973, a select ...... itor of spleen tyrosine kinase

@nl

prefLabel

Discovery of GS-9973, a select ...... itor of spleen tyrosine kinase

@ast

Discovery of GS-9973, a select ...... itor of spleen tyrosine kinase

@en

Discovery of GS-9973, a select ...... itor of spleen tyrosine kinase

@nl

P1433

Q27690120-0DEF4C73-1BB0-45F6-8F7B-615026929929

P1476

Q27690120-24E5B8D0-DE46-4214-BAD1-3F60214C6F0A

P2093

Q27690120-01476962-F2E6-4F3C-81B1-20B007608AC3

Q27690120-22432BA7-CEB2-4994-8982-655B5F83D80E

Q27690120-42E7E630-A2E0-492A-BA5D-DD100A7F4D2E

Q27690120-4A52282B-C8E4-41E1-8610-FD3D63460008

Q27690120-7B8D59DC-5116-4991-B6E4-701D61DDA1AA

Q27690120-92ED6F9E-0555-46E7-91AF-A655BA4E4694

Q27690120-ABB0FB5F-6925-4178-9F90-A4DCCAC677F1

Q27690120-B020621A-C136-49BC-BD8E-B16380D2071D

Q27690120-B3872658-BF88-4E3A-ACB8-8275CC3C739F

Q27690120-B67B5F5C-B069-495E-B406-F4D0C8E828DE

P304

Q27690120-5A3E06BB-2219-4AF6-8ED1-1FC64DAFA823

P31

Q27690120-62E3BCC1-8699-475D-A84C-040E4E103517

P356

Q27690120-532BE01B-985D-4E4D-B318-6D4402F8ECD2

P407

Q27690120-B1F13F94-1622-43C4-A9BC-8C03267FBBD2

P433

Q27690120-A91BD748-650A-42ED-B5E9-FAA7A830B711

P478

Q27690120-C1869BE6-B329-4AFE-B6C0-3AF98226FC0A

P577

Q27690120-14F541BB-8C4D-4FB5-BF18-51AEA0340A92

P5875

Q27690120-CEF80AF7-B843-4606-B56D-A322AF37CF90

P698

Q27690120-8B623637-4C38-40E9-9156-A60A311F5A6E

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery of GS-9973, a select ...... itor of spleen tyrosine kinase

@en

P2093

Ann Marie Rossi

http://www.w3.org/2001/XMLSchema#string

Deborah Maclin

http://www.w3.org/2001/XMLSchema#string

Eric B Lansdon

http://www.w3.org/2001/XMLSchema#string

Hong Rong

http://www.w3.org/2001/XMLSchema#string

J Andrew Whitney

http://www.w3.org/2001/XMLSchema#string

James Barbosa

http://www.w3.org/2001/XMLSchema#string

Jeffrey E Kropf

http://www.w3.org/2001/XMLSchema#string

Jennifer Macaluso

http://www.w3.org/2001/XMLSchema#string

Jianjun Xu

http://www.w3.org/2001/XMLSchema#string

Julie A Di Paolo

http://www.w3.org/2001/XMLSchema#string

P304

3856-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM500228A

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262000002

http://www.w3.org/2001/XMLSchema#string

P698

24779514

http://www.w3.org/2001/XMLSchema#string